These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22437111)

  • 1. CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2894-7. PubMed ID: 22437111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2898-901. PubMed ID: 22421019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2803-6. PubMed ID: 22444677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.
    Kusakabe K; Iso Y; Tada Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
    Bioorg Med Chem; 2013 Jun; 21(11):3154-63. PubMed ID: 23623258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
    Frost JM; Dart MJ; Tietje KR; Garrison TR; Grayson GK; Daza AV; El-Kouhen OF; Yao BB; Hsieh GC; Pai M; Zhu CZ; Chandran P; Meyer MD
    J Med Chem; 2010 Jan; 53(1):295-315. PubMed ID: 19921781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.
    Kusakabe K; Tada Y; Iso Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
    Bioorg Med Chem; 2013 Apr; 21(7):2045-55. PubMed ID: 23395112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
    Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
    J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
    Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
    Manera C; Cascio MG; Benetti V; Allarà M; Tuccinardi T; Martinelli A; Saccomanni G; Vivoli E; Ghelardini C; Di Marzo V; Ferrarini PL
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6505-10. PubMed ID: 17942307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
    Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of cannabinoid receptor ligands: current status.
    Singh J; Budhiraja S
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
    Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
    Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
    Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
    Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
    Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
    Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR
    Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.